Galectin Therapeutics Inc (NASDAQ:GALT) is crash-landing 35% to the market floor once investors caught word of the biotech firm's Phase 2b ... medical director of Pinnacle Clinical Research in San Antonio, Texas, and visiting professor of medicine at the University of Oxford, United Kingdom.
News
- Galectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial Failure
- Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with ...
... in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium ... 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and…
- Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with ...
05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and ... a first-in-class glutaminase inhibitor, will be presented at the 2017 San Antonio Breast Cancer Symposium, December 5-9, 2017 in San Antonio, Texas.
- Galectin drops 40% on negative NASH result
It's rarely ever a positive sign when a biotech has to resort to slicing and dicing data in order to find a positive result. ... for the presence of esophageal varices," said Stephen Harrison, one of lead investigators of the NASH-CX trial and medical director of Pinnacle Clinical Research in…
- SA biotech lining up talent, science and cash in march to market
The San Antonio-based biotech is expanding its leadership team. It's also preparing to launch new clinical trials in support of its lead CyPath Lung ...